ArticleJournal of cardiothoracic surgery2026
Intraoperative pafolacianin for nodule detection during VATS metastasectomy in extremity metastatic sarcoma surgery performed concurrently.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntraoperative molecular imaging using intravenous Pafolacianine (Cytalux) is reported to improve tumor detection in malignant pulmonary and ovarian lesions. Pafolacianine’s affinity for folate receptors in these specific tissues aided in the elucidation of adequate margins for diagnostic and therapeutic resections when administered prior to surgical intervention. The role for Pafolacianine for malignant lesions in other pathologies as well as the time in which Pafolacianine remains bound and fluoroscopically detectable is unknown. CASE PRESENTATION: Presented here is a case of a 27-year-old man found with recurrent malignant peripheral nerve sheath tumor (MPNST) of the right upper extremity who developed a new left lung nodule concerning for metastatic disease. Initially, we performed a left-sided video assisted thoracoscopy surgery (VATS) with perioperative Pafolacianine administration. Allowing us to successfully remove his metastatic pulmonary disease with wedge metastasectomy. Six days later during the reexcision of his MPNST we used the thoracoscopy which enabled us to identify his primary tumor within the left antecubital fossa. Since the primary tumor also emitted a fluoroscopic signal, it aided in resection of the cancerous lesion in a heavily scarred and radiated field.
conclusionTo date, there have been no reported cases of Pafolacianine retention within extra-pulmonary and ovarian tumor cells after an extended period of time. We believe our case demonstrates the prospective application and effectiveness of Pafolacianine in targeting cancer cells by fluorescence-guided resection. In summary, we theorize that there is a role for Pafolacianine in identifying malignant lesions regardless of tumor location. In addition, the retention of Pafolacianine within high folate acid receptor expressing cells is at least if not more than 6 days implying that the drug does not need to be readministered if additional resection is needed .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.